BrightSpring (NASDAQ: BTSG) hikes 2026 revenue and Adjusted EBITDA guidance

Rhea-AI Filing Summary

BrightSpring Health Services reported sharply improved first quarter 2026 results and raised its full year outlook. Total revenue reached $3.61 billion for the quarter ended March 31, 2026, compared with $2.88 billion a year earlier, with growth in both products and services.

Net income rose to $148.6 million from $29.0 million, including higher income from continuing and discontinued operations. Adjusted EBITDA increased to $189.8 million, up from $131.1 million, while diluted EPS from continuing operations was $0.34 and Adjusted EPS was $0.39. Operating cash flow strengthened to $122.9 million, and cash and cash equivalents climbed to $888.8 million.

For full year 2026, the company now guides to revenue of $14.7–$15.2 billion and total Adjusted EBITDA of $795–$825 million, both higher than prior 2025 results on a comparable basis. Management expects the Amedysis and LHC acquisition to contribute about $30 million of Adjusted EBITDA in 2026.

Positive

• Stronger profitability and cash flow: Q1 2026 net income rose to $148.6 million from $29.0 million, Adjusted EBITDA reached $189.8 million versus $131.1 million, and operating cash flow increased to $122.9 million, with cash and cash equivalents at $888.8 million.
• Raised 2026 outlook with acquisition contribution: 2026 revenue guidance is now $14.725–$15.225 billion and Adjusted EBITDA $795–$825 million, including an expected ~$30 million Adjusted EBITDA contribution from the Amedysis and LHC acquisition.

Negative

• None.

Insights

Equity analyst

BrightSpring posts strong Q1 growth and raises 2026 revenue and EBITDA guidance.

BrightSpring Health Services delivered a sizable step-up in profitability. Q1 2026 revenue was $3.61 billion, with operating income of $121.4 million versus $50.7 million a year earlier. Net income from continuing operations increased to $74.3 million, supporting diluted EPS of $0.34.

Non-GAAP metrics also strengthened. Adjusted EBITDA reached $189.8 million, up from $131.1 million. Adjusted EPS was $0.39 compared with $0.19. Cash generation improved, with operating cash flow of $122.9 million and period-end cash of $888.8 million, aided by proceeds from discontinued operations.

Full year 2026 guidance now calls for revenue of $14.725–$15.225 billion and Adjusted EBITDA of $795–$825 million. The company also expects about $30 million of Adjusted EBITDA from the Amedysis and LHC acquisition in 2026. Subsequent filings may provide more color on segment performance against these targets.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Q1 2026 Revenue: $3,613,721,000 Q1 2026 Net Income: $148,610,000 Q1 2026 Adjusted EBITDA: $189,761,000 +5 more

8 metrics

Q1 2026 Revenue $3,613,721,000 Total revenues for the three months ended March 31, 2026

Q1 2026 Net Income $148,610,000 Net income for the three months ended March 31, 2026

Q1 2026 Adjusted EBITDA $189,761,000 Adjusted EBITDA for the three months ended March 31, 2026

Q1 2026 Diluted EPS (continuing ops) $0.34 per share Diluted EPS from continuing operations for Q1 2026

Q1 2026 Adjusted EPS $0.39 per share Adjusted EPS for the three months ended March 31, 2026

2026 Revenue Guidance $14,725,000,000–$15,225,000,000 Full year 2026 revenue outlook excluding Community Living

2026 Adjusted EBITDA Guidance $795,000,000–$825,000,000 Full year 2026 Adjusted EBITDA outlook

Expected 2026 EBITDA from Amedysis and LHC $30,000,000 Estimated 2026 Adjusted EBITDA contribution from acquisition

Key Terms

Adjusted EBITDA, Adjusted EPS, discontinued operations, redeemable noncontrolling interests, +2 more

6 terms

Adjusted EBITDA financial

"Total Adjusted EBITDA5 of $795 million to $825 million, or 28.7% to 33.6% growth."

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

Adjusted EPS financial

"This press release contains “non-GAAP financial measures,” including “EBITDA,” “Adjusted EBITDA,” and “Adjusted EPS,”"

Adjusted earnings per share (adjusted eps) is a measure of a company's profit per share that has been modified to exclude certain one-time or unusual items, such as costs from restructuring or asset sales. It provides a clearer picture of the company’s core performance by removing events that may distort the usual earnings. Investors use adjusted eps to better understand a company's ongoing profitability and compare it more accurately over time.

discontinued operations financial

"Income from discontinued operations, net of income taxes"

Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.

redeemable noncontrolling interests financial

"Redeemable noncontrolling interests | | | 10,512 | | | | 11,227 |"

A redeemable noncontrolling interest is a minority ownership stake in a company that the holder can force the company to buy back at a set price or under certain conditions. For investors this matters because it creates a future cash obligation and can be treated more like a liability than permanent equity, affecting a company’s reported debt, net income and valuation — think of it as a part-owner who can cash out, forcing the business to pay them.

forward-looking statements regulatory

"This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Non-GAAP financial measures financial

"This press release contains “non-GAAP financial measures,” including “EBITDA,” “Adjusted EBITDA,” and “Adjusted EPS,”"

Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.

Earnings Snapshot

Revenue: $3,613,721,000 · Guidance included

Q1 2026

Revenue $3,613,721,000 vs $2,878,129,000 in Q1 2025

Net income $148,610,000 vs $29,010,000 in Q1 2025

Adjusted EBITDA $189,761,000 vs $131,062,000 in Q1 2025

Diluted EPS (continuing ops) $0.34 vs $0.05 in Q1 2025

Adjusted EPS $0.39 vs $0.19 in Q1 2025

Guidance

2026 revenue guidance of $14.725–$15.225 billion and Adjusted EBITDA guidance of $795–$825 million, excluding the Community Living business.

Understanding 8-K Material Events →

0001865782false00018657822026-05-012026-05-010001865782us-gaap:CommonStockMember2026-05-012026-05-010001865782btsg:SixPointSevenFivePercentageTangibleEquityUnitsMember2026-05-012026-05-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 01, 2026

BrightSpring Health Services, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41938	82-2956404
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
805 N. Whittington Parkway
Louisville, Kentucky				40222
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 502 394-2100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		BTSG		The Nasdaq Stock Market LLC
6.75% Tangible Equity Units		BTSGU		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 1, 2026, BrightSpring Health Services, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 2.02.

The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release of BrightSpring Health Services, Inc., dated May 1, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			BRIGHTSPRING HEALTH SERVICES, INC.
Date:	May 1, 2026	By:	/s/ Jennifer Phipps
		Name: Title:	Jennifer Phipps Executive Vice President and Chief Financial Officer

BrightSpring Health Services, Inc. Reports First Quarter 2026 Financial Results and Increases Full Year 2026 Guidance

LOUISVILLE, Ky., May 1, 2026 — BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the first quarter ended March 31, 2026, and increased full year 2026 Revenue and Adjusted EBITDA1 guidance.

First Quarter 2026 Financial Highlights

(note: all figures represent continuing operations and exclude the Community Living business)

•Net revenue of $3,614 million, up 25.6% compared to $2,878 million in the first quarter of 2025

•Gross profit of $482 million, up 42.5% compared to $338 million in the first quarter of 2025

•Net income of $74 million compared to $9 million in the first quarter of 2025

•Adjusted EBITDA1 of $190 million, up 44.8% compared to $131 million in the first quarter of 2025

•Leverage2 of 2.27x as of March 31, 2026, compared to pro forma leverage3 of 2.60x on December 31, 2025, both of which exclude the impact of the Community Living divestiture

•Divestiture of Community Living business to Sevita closed on March 30, 2026, which resulted in a $31.2 million gain on sale, net of tax recorded within discontinued operations

•Completion of an underwritten secondary offering of our common stock by affiliates of Kohlberg Kravis Roberts & Co. L.P. and certain members of management in March 2026, and a concurrent $60.0 million repurchase of 1,464,807 shares of common stock from the underwriter

"We are pleased with the Company’s first quarter results, which reflect the team’s commitment to patients as well as the operating and growth priorities discussed at the Investor Day in March,” said Jon Rousseau, Chairman, President, and Chief Executive Officer of BrightSpring. “Our focus continues to be anchored in operational and commercial best practices across the organization while leveraging scale to provide quality and effective services to complex patient populations. As we look ahead to the remainder of 2026, we are focused on growing each of our businesses while executing against our goals and reaching more patients who can benefit from these highly impactful and valuable services.”

1Adjusted EBITDA is a non-GAAP financial measure. Please see “Non-GAAP Financial Information” at the end of this press release for a reconciliation of Adjusted EBITDA to net income from continuing operations, the most directly comparable financial measure prepared in accordance with GAAP.

2The results of the Community Living business are excluded in the calculation of our leverage pursuant to the terms of our First Lien Credit Agreement since the Company divested the Community Living business prior to the end of the period.

3Leverage is presented on a pro forma basis assuming the Community Living divestiture closed as of December 31, 2025.

1

Key Financials4 (for BrightSpring continuing operations)

		Three Months Ended
		March 31, (Unaudited)
		2026			2025			%
($ in millions)
Pharmacy Solutions Revenue		$	3,171		$	2,532		25%
Provider Services Revenue			442			346		28%
Total Revenue		$	3,614		$	2,878		26%

		Three Months Ended
		March 31, (Unaudited)
		2026			2025			%
($ in millions)
Pharmacy Solutions segment EBITDA		$	169		$	116		46%
Provider Services segment EBITDA			66			51		29%
Total Segment Adjusted EBITDA		$	235		$	167		41%
Corporate Costs			(45)			(36)		-
Total Company Adjusted EBITDA(1)		$	190		$	131		45%

Business Metrics

		Three Months Ended
		March 31, (Unaudited)
		2026			2025			%
Pharmacy Solutions
Prescriptions dispensed		10,729,876			10,877,294			(1%)
Revenue per script ($)			295.56			232.79		27%
Gross Profit per script ($)			28.03			18.75		50%
Provider Services
Home Health Care average daily census			46,066			30,241		52%
Rehab Care persons served			7,620			6,697		14%
Personal Care persons served			16,079			15,863		1%

1Adjusted EBITDA is a non-GAAP financial measure. Please see “Non-GAAP Financial Information” and the end of this press release for a reconciliation of Adjusted EBITDA to net income from continuing operations, the most directly comparable financial measure prepared in accordance with GAAP.

4Financial tables may not foot due to rounding.

2

Full Year 2026 Financial Guidance

For the full year 2026, BrightSpring is increasing Revenue and Adjusted EBITDA guidance, which excludes the Community Living business and the effects of any future closed acquisitions. All growth rates are shown as compared to the full year 2025 Revenue and Adjusted EBITDA results, excluding the Community Living business:

•Revenues of $14,725 million to $15,225 million, or 14.1% to 17.9% growth.

oPharmacy Segment Revenue of $12,850 million to $13,300 million, or 12.3% to 16.2% growth.

oProvider Segment Revenue of $1,875 million to $1,925 million, or 28.0% to 31.4% growth.

•Total Adjusted EBITDA5 of $795 million to $825 million, or 28.7% to 33.6% growth.

•The Amedysis and LHC acquisition is expected to contribute approximately $30 million in Adjusted EBITDA in 2026.

5A reconciliation of the foregoing guidance for the non-GAAP metric of Adjusted EBITDA to GAAP net income from continuing operations cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.

Webcast and Conference Call Details

The Company will host a conference call today, May 1st at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call are required to register online.

A live and archived webcast of the event will be available on the “Events & Presentations” section of the BrightSpring website at https://ir.brightspringhealth.com/. The Company has posted supplemental information on the first quarter 2026 results that it will reference during the conference call. The supplemental information can be found under the “Events & Presentations” on the Company’s investor relations page.

About BrightSpring Health Services

BrightSpring Health Services provides complementary home- and community-based health solutions for complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care, and rehabilitation, we provide comprehensive and more integrated care and clinical solutions in all 50 states to over 475,000 customers, clients and patients daily. BrightSpring has consistently demonstrated strong and industry-leading quality metrics across its services lines, while improving the health and quality of life for high-need individuals and reducing overall healthcare system costs.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-looking statements may relate to matters which include, but are not limited to, industries, business strategy, goals and expectations concerning our market position, future operations,

3

margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. In some cases, we have used words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” “target,” “guidance,” the negative version of these words, or similar terms and phrases to identify these forward-looking statements.

The forward-looking statements are based on management’s current expectations and are not historical facts or guarantees of future performance. The forward-looking statements relate to the future and are therefore subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following:

•our operation in a highly competitive industry;

•our inability to maintain relationships with existing patient referral sources or establish new referral sources;

•changes to Medicare and Medicaid rates or methods governing Medicare and Medicaid payments for our services;

•cost containment initiatives of third-party payors, including post-payment audits;

•the implementation of alternative payment models and the transition of Medicaid and Medicare beneficiaries to managed care organizations may limit our market share and could adversely affect our revenues;

•changes in the case mix of patients, as well as payor mix and payment methodologies, and decisions and operations of third-party organizations;

•our reliance on federal and state spending, budget decisions, and continuous governmental operations which may fluctuate under different political conditions;

•changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement, which may negatively impact our profitability;

•changes in our relationships with pharmaceutical suppliers, including changes in drug availability or pricing;

•reliance on the continual recruitment and retention of nurses, pharmacists, therapists, caregivers, direct support professionals, and other qualified personnel, including senior management;

•compliance with or changes to federal, state, and local laws and regulations that govern our employment practices, including minimum wage, living wage, and paid time-off requirements;

•fluctuation of our results of operations on a quarterly basis;

•harm caused by labor relation matters;

•limitations in our ability to control reimbursement rates received for our services if we are unable to maintain or reduce our costs to provide such services;

•delays in collection or non-collection of our accounts receivable, particularly during the business integration process;

•failure to manage our growth effectively, which may inhibit our ability to execute our business plan, maintain high levels of service and satisfaction or adequately address competitive challenges;

•our ability to identify, successfully complete and manage acquisitions, joint ventures, divestitures and other significant transactions and strategic initiatives;

•our ability to continue to provide consistently high quality of care;

4

•maintenance of our corporate reputation or the emergence of adverse publicity, including negative information on social media or changes in public perception of our services;

•contract continuance, expansion and renewal with our existing customers, including renewals at lower fee levels, customers declining to purchase additional services from us, or reduction in the services received from us pursuant to those contracts;

•effective investment in, implementation of improvements to and proper maintenance of the uninterrupted operation and data integrity of our information technology and other business systems;

•security breaches, loss of data, and other disruptions, which could compromise sensitive business or patient information; cause a loss of confidential patient data, employee data or personal information; or prevent access to critical information and thereby expose us to liability, litigation, and federal and state governmental inquiries and damage our reputation and brand;

•risks related to credit card payments and other payment methods;

•potential substantial malpractice or other similar claims;

•various risks related to governmental inquiries, regulatory actions, and whistleblower and other lawsuits, which may not be entirely covered by insurance;

•our current insurance program, which may expose us to unexpected costs, particularly if we incur losses not covered by our insurance or if claims or losses differ from our estimates;

•factors outside of our control, including those listed, which have required and could in the future require us to record an asset impairment of goodwill;

•a pandemic, epidemic, or outbreak of an infectious disease;

•inclement weather, natural disasters, acts of terrorism, riots, civil insurrection or social unrest, looting, protests, strikes, or street demonstrations;

•our inability to adequately protect our intellectual property rights;

•risks related to our compliance with our regulatory framework;

•the significant interests of KKR Stockholder may conflict with our stockholders’ interests in the future;

•our substantial indebtedness;

•significant changes in tax or trade policies, tariffs, or trade relations between the United States and other countries, such as the imposition of unilateral tariffs on imported products, including impacts on imported drug products, which could result in supply chain disruptions and significant increases in costs; and

•fluctuations in the amount and frequency of repurchases of our common stock.

The forward-looking statements included in this press release are made only as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law. These factors should not be construed as exhaustive, and should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward- looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make.

For additional information on these and other factors that could cause BrightSpring’s actual results to differ materially from expected results, please see our filings with the Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

5

Non-GAAP Financial Measures

This press release contains “non-GAAP financial measures,” including “EBITDA,” “Adjusted EBITDA,” and “Adjusted EPS,” which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with accounting principles generally accepted in the United States, or GAAP.

EBITDA, Adjusted EBITDA, and Adjusted EPS have been presented in this release as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP, because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management also believes that these measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses EBITDA, Adjusted EBITDA, and Adjusted EPS to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish and award discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures.

Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone. EBITDA, Adjusted EBITDA, and Adjusted EPS are non-GAAP measures of our financial performance and should not be considered as an alternative to net income as a measure of financial performance or any other performance measures derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management’s discretionary use as they do not consider certain cash requirements such as tax payments, debt service requirements, total capital expenditures, and certain other cash costs that may recur in the future.

Management defines EBITDA as net income from continuing operations before income tax expense (benefit), interest expense, net and depreciation and amortization. Management also defines Adjusted EBITDA as EBITDA, further adjusted to exclude non-cash share-based compensation, acquisition, integration and transaction-related costs, and restructuring and divestiture-related and other costs.

The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. Please see the end of this press release for reconciliations of non-GAAP financial measures to the most directly comparable financial measure prepared in accordance with GAAP.

BrightSpring Contact:

Investor Relations:	Media Contact:
David Deuchler, CFA	Leigh White
Gilmartin Group LLC	leigh.white@brightspringhealth.com
ir@brightspringhealth.com	502.630.7412

6

BrightSpring Health Services, Inc. and Subsidiaries

Consolidated Balance Sheets

March 31, 2026 and December 31, 2025

(In thousands, except share and per share data)

(Unaudited)

		March 31, 2026				December 31, 2025
Assets
Current assets:
Cash and cash equivalents		$	888,797			$	88,370
Accounts receivable, net of allowance for credit losses			1,113,534				989,719
Inventories			560,166				815,180
Prepaid expenses and other current assets			126,806				118,592
Current assets held for sale			—				882,189
Total current assets			2,689,303				2,894,050
Property and equipment, net of accumulated depreciation of $421,329 and $404,878 at     March 31, 2026 and December 31, 2025, respectively			201,885				204,689
Goodwill			2,533,555				2,545,673
Intangible assets, net of accumulated amortization			536,884				557,555
Operating lease right-of-use assets, net			173,333				171,632
Other assets			78,354				39,712
Total assets		$	6,213,314			$	6,413,311
Liabilities, Redeemable Noncontrolling Interests, and Equity
Current liabilities:
Trade accounts payable		$	1,091,434			$	1,217,946
Accrued expenses			351,891				333,024
Current portion of obligations under operating leases			45,391				42,936
Current portion of obligations under financing leases			6,737				6,794
Current portion of long-term debt			52,960				52,340
Current liabilities held for sale			—				195,994
Total current liabilities			1,548,413				1,849,034
Obligations under operating leases, net of current portion			136,724				135,420
Obligations under financing leases, net of current portion			13,021				14,544
Long-term debt, net of current portion			2,444,871				2,455,204
Deferred income taxes, net			1,166				6,178
Long-term liabilities			79,226				66,565
Total liabilities			4,223,421				4,526,945
Redeemable noncontrolling interests			10,512				11,227
Shareholders' equity:
Common stock, $0.01 par value, 1,500,000,000 shares authorized, 193,209,722 and    192,124,125 shares issued and outstanding at March 31, 2026 and December 31, 2025,    respectively		$	1,932			$	1,921
Preferred stock, $0.01 par value, 250,000,000 authorized, no shares issued and    outstanding at March 31, 2026 and December 31, 2025			—				—
Additional paid-in capital			1,964,516				1,954,482
Retained earnings (accumulated deficit)			14,135				(74,647	)
Accumulated other comprehensive loss			(1,265	)			(6,691	)
Total shareholders' equity			1,979,318				1,875,065
Noncontrolling interest			63				74
Total equity			1,979,381				1,875,139
Total liabilities, redeemable noncontrolling interests, and equity		$	6,213,314			$	6,413,311

BrightSpring Health Services, Inc. and Subsidiaries

Consolidated Statements of Operations

For the three months ended March 31, 2026 and 2025

(In thousands, except per share amounts)

(Unaudited)

		For the Three Months Ended
		March 31,
		2026				2025
Revenues:
Products		$	3,171,349			$	2,532,171
Services			442,372				345,958
Total revenues			3,613,721				2,878,129
Cost of goods			2,870,575				2,328,215
Cost of services			260,924				211,545
Gross profit			482,222				338,369
Selling, general, and administrative expenses			360,773				287,630
Operating income			121,449				50,739
Interest expense, net			38,615				41,763
Income from continuing operations before income taxes			82,834				8,976
Income tax expense (benefit)			8,551				(240	)
Income from continuing operations, net of income taxes			74,283				9,216
Income from discontinued operations, net of income taxes			74,327				19,794
Net income			148,610				29,010
Net loss attributable to noncontrolling interests included in continuing operations			(157	)			(532	)
Net income attributable to BrightSpring Health Services, Inc. and subsidiaries		$	148,767			$	29,542
Net income per common share:
Basic income per share attributable to common shareholders:
Continuing operations		$	0.36			$	0.05
Discontinued operations		$	0.37			$	0.10
Net income per share		$	0.73			$	0.15
Diluted income per share attributable to common shareholders:
Continuing operations		$	0.34			$	0.05
Discontinued operations		$	0.33			$	0.09
Net income per share		$	0.67			$	0.14
Weighted average shares outstanding:
Basic			204,712				201,005
Diluted			221,321				214,927

BrightSpring Health Services, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

For the three months ended March 31, 2026 and 2025

(In thousands)

(Unaudited)

		For the Three Months Ended
		March 31,
		2026				2025
Operating activities:
Net income		$	148,610			$	29,010
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization			39,094				42,161
Change in fair value of contingent consideration, net			—				1,698
Provision for credit losses			10,559				8,101
Amortization of deferred debt issuance costs			2,816				2,749
Share-based compensation			3,676				15,681
Deferred income taxes, net			(7,193	)			4,031
Gain on sale of discontinued operations			(103,412	)			—
Other			(72	)			2,919
Change in operating assets and liabilities, net of acquisitions and dispositions:
Accounts receivable			(114,125	)			(79,449	)
Prepaid expenses and other current assets			(7,791	)			23,973
Inventories			254,833				103,300
Trade accounts payable			(86,987	)			(53,871	)
Accrued expenses			11,030				8,643
Other assets and liabilities			(28,095	)			(7,348	)
Net cash provided by operating activities		$	122,943			$	101,598
Investing activities:
Purchases of property and equipment		$	(21,544	)		$	(17,632	)
Acquisitions of businesses			(42,203	)			(6,754	)
Proceeds from sale of discontinued operations			810,908				—
Other			232				195
Net cash provided by (used in) investing activities		$	747,393			$	(24,191	)
Financing activities:
Long-term debt repayments		$	(12,353	)		$	(11,792	)
Repayments of the Revolving Credit Facility, net			—				(63,300	)
Repurchase of shares of common stock			(60,000	)			—
Proceeds from shares issued under share-based compensation plan			12,092				345
Taxes paid related to net share settlement of equity awards			(5,708	)			(2,763	)
Purchase of redeemable noncontrolling interest			—				(5,100	)
Payments of financing lease obligations			(4,047	)			(3,408	)
Net cash used in financing activities		$	(70,016	)		$	(86,018	)
Net increase (decrease) in cash and cash equivalents			800,320				(8,611	)
Cash and cash equivalents at beginning of period			88,477				61,253
Cash and cash equivalents at end of period		$	888,797			$	52,642
Cash and cash equivalents included in assets held for sale at end of period			—				305
Cash and cash equivalents included in continuing operations at end of period		$	888,797			$	52,337

BrightSpring Health Services, Inc. and Subsidiaries

Reconciliation of EBITDA and Adjusted EBITDA

For the three months ended March 31, 2026 and 2025

(Unaudited)

The following table reconciles net income from continuing operations to EBITDA and Adjusted EBITDA:

($ in thousands)		For the Three Months Ended
		March 31,
		2026				2025
Net income from continuing operations		$	74,283			$	9,216
Income tax expense (benefit)			8,551				(240	)
Interest expense, net			38,615				41,763
Depreciation and amortization			39,094				40,832
EBITDA		$	160,543			$	91,571
Non-cash share-based compensation (1)			13,116				12,474
Acquisition, integration, and transaction-related costs (2)			6,100				9,521
Restructuring and divestiture-related and other costs (3)			10,002				17,496
Total adjustments		$	29,218			$	39,491
Adjusted EBITDA		$	189,761			$	131,062

(1)Represents non-cash share-based compensation to certain members of our management and full-time employees.

(2)Represents transaction costs incurred in connection with planned, completed, or terminated acquisitions, which include investment banking fees, legal diligence and related documentation costs, finance and accounting diligence and documentation; costs associated with the integration of acquisitions, including any facility consolidation, integration travel, or severance; and costs associated with other planned, completed, or terminated non-routine transactions.

(3)Represents costs associated with restructuring-related activities, including closure, and related license impairment, and severance expenses associated with certain enterprise-wide or significant business line cost-savings measures.

BrightSpring Health Services, Inc. and Subsidiaries

Reconciliation of Adjusted EPS

For the three months ended March 31, 2026 and 2025

(Unaudited)

The following table reconciles diluted EPS to Adjusted EPS:

(shares in thousands)		For the Three Months Ended
		March 31,
		2026				2025
Diluted EPS		$	0.34			$	0.05
Non-cash share-based compensation (1)			0.06				0.06
Acquisition, integration, and transaction-related costs (1)			0.03				0.04
Restructuring and divestiture-related and other costs (1)			0.05				0.08
Income tax impact on adjustments (2)			(0.09	)			(0.04	)
Adjusted EPS		$	0.39			$	0.19
Weighted average common shares outstanding used in calculating      diluted U.S. GAAP net income per share			221,321				214,927
Weighted average common shares outstanding used in calculating      diluted Non-GAAP income per share			221,321				214,927

(1) This adjustment reflects the per share impact of the adjustment reflected within the definition of Adjusted EBITDA.

(2) The income tax impact of non-GAAP adjustments is calculated using the estimated tax rate for the respective non-GAAP adjustment. For all periods presented, the income tax impact on adjustments is inclusive of a discrete tax benefit related to share-based compensation.

FAQ

How did BrightSpring (BTSG) perform financially in Q1 2026?

BrightSpring delivered significantly improved Q1 2026 results, with revenue of $3.61 billion versus $2.88 billion a year earlier. Net income reached $148.6 million, up from $29.0 million, reflecting stronger operating performance and higher income from both continuing and discontinued operations.

What was BrightSpring’s Adjusted EBITDA in Q1 2026?

In Q1 2026, BrightSpring reported Adjusted EBITDA of $189.8 million, compared with $131.1 million in Q1 2025. This non-GAAP measure adds back items like share-based compensation and transaction-related costs to EBITDA, helping investors track underlying operating performance across periods.

What full year 2026 revenue guidance did BrightSpring (BTSG) provide?

For full year 2026, BrightSpring guides to revenue of $14.725–$15.225 billion, representing double-digit growth versus 2025 on a comparable basis. The outlook includes Pharmacy Segment revenue of $12.85–$13.30 billion and Provider Segment revenue of $1.875–$1.925 billion.

What is BrightSpring’s 2026 Adjusted EBITDA guidance?

BrightSpring expects full year 2026 Adjusted EBITDA of $795–$825 million, indicating substantial growth over 2025 results excluding the Community Living business. Management notes that a reconciliation to GAAP net income cannot be provided because future adjusting items are difficult to forecast reliably.

How much Adjusted EBITDA is expected from the Amedysis and LHC acquisition in 2026?

BrightSpring expects the Amedysis and LHC acquisition to contribute about $30 million of Adjusted EBITDA in 2026. This expected contribution is included within the company’s overall Adjusted EBITDA guidance range and reflects integration of the acquired home health assets into its operations.

What were BrightSpring’s Q1 2026 earnings per share metrics?

For Q1 2026, BrightSpring reported diluted EPS from continuing operations of $0.34 versus $0.05 a year earlier. Adjusted EPS was $0.39, compared with $0.19, reflecting adjustments for non-cash share-based compensation, transaction-related costs, and restructuring and divestiture-related items.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 641.9 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 44.5 KB